Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Mesoblast Limited (MESO) vs iShares 0 3 Month Treasury Bond ETF (SGOV) Price & Performance

Mesoblast LimitedTrade
iShares 0 3 Month Treasury Bond ETFTrade

Price performance (Past 24H)

Key statistics

Mesoblast Limited vs iShares 0 3 Month Treasury Bond ETF — how do they compare? Mesoblast Limited trades at $16.32 (market cap $2.17B), while iShares 0 3 Month Treasury Bond ETF trades at $100.6. The key difference: iShares 0 3 Month Treasury Bond ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.

MESOSGOV
Market Cap
$2.17B
Sector
TechnologyFixed Income
52-Week High
$20.96$100.74
52-Week Low
$12.88$100.28
Enterprise Value
$2.17B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Mesoblast Limited

MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.

Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.

iShares 0 3 Month Treasury Bond ETF

SGOV, the iShares 0-3 Month Treasury Bond ETF, trades at $100.59, up slightly by 0.01% today. Technical indicators show a bullish trend with strong moving average support, though oscillators are neutral. The ETF provides exposure to short-term U.S. Treasury bills, offering liquidity and a low expense ratio of 0.09%. Recent news highlights institutional interest, such as Advisortrust Partners LLC acquiring a $615,000 position.

The outlook for SGOV is stable, benefiting from its role as a cash management tool amid rate uncertainty. Investment appeal lies in its safety and yield relative to cash, but risks include potential Fed rate hikes impacting short-term bond prices. Investors seeking low-risk income may find SGOV attractive, though returns are modest compared to equities.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO

About iShares 0 3 Month Treasury Bond ETF

SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.

Read more on SGOV